S100 protein family and its application in clinical practice

Hippokratia

Volumn 12, Issue 4, 2008, Pages 198-204

  Sedaghat, F ^a   Notopoulos, A ^a,b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Hippokratio General Hospital ^*  (Greece)

Author keywords

Malignant melanoma; Neurodegenerative disorders; Protein S100B; S100 protein family; Traumatic brain injury

Indexed keywords

ADVANCED GLYCATION END PRODUCT; PROTEIN P53; PROTEIN S 100; PROTEIN S100B;

ALZHEIMER DISEASE; ASTROCYTE; CELL ACTIVATION; CLINICAL PRACTICE; HEART ARREST; INTRAUTERINE GROWTH RETARDATION; MELANOMA; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN STRUCTURE; RESUSCITATION; REVIEW; SUBARACHNOID HEMORRHAGE; TRAUMATIC BRAIN INJURY;

EID: 53849144684     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 1965; 19: 739-744
2. Marenholz I, Heinzman CW, Fritz G. S100 protein in mouse and man: from evolution to function and pathology. Biochem Biophys Res Commun 2004; 322: 1111-1122
3. Michetti F, Gazzolo D. S100B protein in biological fluids: a tool for perinatal medicine. Clin Chem 2002; 48: 2097-2104
4. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003; 60: 540-551
5. Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS. Calcium -dependent and -independent interactions of the S100 protein family. Biochem J 2006; 396: 201-214
6. Ikura M. Calcium binding and conformational response in EF-hand proteins. Trends Biochem Sci 1996; 21: 14-17
7. Eckert RL, Broome A-M, Ruse M, Robinson N, Ryan D, Lee K. S100 proteins in the epidermis. J Invest Dermatol 2004; 123: 23-33
8. Nishikawa T, Lee ISM, Shiraishi T, Ishikawa T, Ohta Y, Nishikimi M. Identification of S100b protein as copper-binding protein and its suppression of copper-induced cell damage. J Biol Chem 1997; 272: 23037-23041
9. Schafer BW, Fritschy JM, Murmann P, et al. Brain S100A5 is a novel calcium-zinc-, and copper ion-binding protein of the EF-hand superfamily. J Biol Chem 2000; 275: 30623-30630
10. - -binding protein family. Biometals 1998; 11: 383-397
11. Yu WH, Fraser PE. S100b interaction with tau is promoted by zinc and inhibited by hyperphosphorylation in Alzheimer's disease. J Neurosci 2001; 21: 2240-2246
12. Shiraishi N, Nishikimi M. Suppression of copper-induced cellular damage by copper sequestration with S100b protein. Arch Biochem Biophys 1998; 357: 225-230
13. Nacken W, Mooren FC, Manitz MP, Bond G, Sorg C, Kerkhoff C. S100A9 deficiency alters adenosine-5′-triphosphate induced calcium signalling but does not generally interfere with calcium and zinc homeostasis in murine neutrophils. Int J Biochem Cell Biol 2005; 37: 1241-1253
14. Newton RA, Hogg N. The human S100 protein MRP-14 is a novel activator of the b2 integrin Mac-1 on neutrophils. J Immunol 1998; 160: 1427-1435
15. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 2000; 275: 40096-40105
16. Korfias S, Stranjalis G, Papadimitriou A, et al. Serum S-100B protein as a biochemical marker of brain injury: a review of current concepts. Curr Med Chem 2006; 13: 3719-3731
17. Ambartsumian N, Klingelhofer J, Grigorian M, et al. The metastasis associated Mts1 (S100A4) protein could act as an angiogenic factor. Oncogene 2001; 20: 4685-4695
18. AB Sangtec Medical, Sangtec 100 IRMA; Immunoradiometric assay for the quantification of protein S100B. Instruction for use 2000
19. nd ed. London: Nature Publishing Group; 2001. p. 660
20. Steiner J, Bernstein HG, Bielau H, et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci 2007; 8: 2
21. Ponath G, Schettler C, Kaestner F, et al. Autocrine S100B effects on astrocytes are mediated via RAGE. J Neuroimmunol 2007; 184: 214-222
22. Gerlach R, Demel G, Konig HG, et al. Active secretion of S100B from astrocytes during metabolic stress. Neuroscience 2006; 141: 1697-1701
23. Scaccianoce S, Del Bianco P, Pannitteri G, Passarelli F. Relationship between stress and circulating levels of S100B protein. Brain Res 2004; 1004: 208-211
24. de Boussard CN, Lundin A, Karlstedt D, Edman G, Bartfai A, Borg J. S100 and cognitive impairment after mild traumatic brain injury. J Rehabil Med 2005; 37: 53-57
25. Bazarian JJ, Zemlan FP, Mookerjee S, Stigbrand T. Serum S100B and cleaved-tau are poor predictors of long-term outcome after mild traumatic brain injury. Brain Inj 2006; 20: 759-765
26. Piazza O, Storti MP, Cotena S, et al. S100B is not a reliable prognostic index in paediatric TBI. Pediatr Neurosurg 2007; 43: 258-264
27. Biberthaler P, Linsenmeier U, Pfeifer KJ, et al. Serum S-100B concentration provides additional information for the indication of computed tomography in patients after minor head injury: a prospective multicenter study. Shock 2006; 25: 446-453
28. Muller K, Townend W, Biasca N, et al. S100B serum level predicts computed tomography findings after minor head injury. J Trauma 2007; 62: 1452-1456
29. Nylen K, Ost M, Csajbok LZ, et al. Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury. Acta Neurochir (Wien) 2008; 150: 221-227.
30. Netto CB, Conte S, Leite MC, et al. Serum S100B protein is increased in fasting rats. Arch Med Res 2006; 37: 683-686
31. Kleindienst A, Ross Bullock M. A critical analysis of the role of the neurotrophic protein S100B in acute brain injury. J Neurotrauma 2006; 23: 1185-1200
32. Ellis EF, Willoughby KA, Sparks SA, Chen T. S100B protein is released from rat neonatal neurons, astrocytes, and microglia by in vitro trauma and anti-S100 increases trauma-induced delayed neuronal injury and negates the protective effect of exogenous S100B on neurons. J Neurochem 2007; 101: 1463-1470
33. Murabayashi M, Minato M, Okuhata Y, et al. Kinetics of serum S100B in newborns with intracranial lesions. Pediatr Int 2008; 50: 17-22
34. Stuart A, Edvinsson L, Kallen K, Olofsson P, Hellsten C, AmerWahlin I. Fetal electrocardiographic monitoring during labor in relation to cord blood levels of the brain-injury marker protein S-100. J Perinat Med 2008; 36: 136-141
35. Vos PE, van Gils M, Beems T, Zimmerman C, Verbeek MM. Increased GFAP and S100beta but not NSE serum levels after subarachnoid haemorrhage are associated with clinical severity. Eur J Neurol 2006; 13: 632-638
36. Oertel M, Schumacher U, McArthur DL, Kastner S, Boker DK. S-100B and NSE: markers of initial impact of subarachnoid haemorrhage and their relation to vasospasm and outcome. J Clin Neurosci 2006; 13: 834-840
37. Li Y, Wang J, Sheng JG, et al. S100 b increases levels of b-amyloid precursor protein and its encoding mRNA in rat neuronal cultures. J Neurochem 1998; 71: 1421-1428
38. Sheng JG, Mrak RE, Griffin WS. S100 b protein expression in Alzheimer disease: potential role in the pathogenesis of neuritic plaques. J Neurosci Res 1994; 39: 398-404
39. Van Eldik LJ, Griffin WS. S100 b expression in Alzheimer's disease: relation to neuropathology in brain regions. Biochim Biophys Acta 1994; 1223: 398-403
40. Foerch C, Wunderlich MT, Dvorak F, et al. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke 2007; 38: 2491-2495
41. Sussmuth SD, Tumani H, Ecker D, Ludolph AC. Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 b in cerebrospinal fluid and creatine kinase in serum. Neurosci Lett 2003; 353: 57-60
42. Hoyaux D, Decaestecker C, Heizmann CW, et al. S100 proteins in corpora amylacea from normal human brain. Brain Res 2000; 867: 280-288
43. Koch M, Mostert J, Heersema D, Teelken A, De Keyser J. Plasma S100beta and NSE levels and progression in multiple sclerosis. J Neurol Sci 2007; 252: 154-158
44. Rejdak K, Petzold A, Stelmasiak Z, Giovannoni G. Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. Mult Scler 2008; 14: 59-66
45. Schenatto CB, Xavier RM, Bredemeier M, et al. Raised serum S100B protein levels in neuropsychiatric lupus. Ann Rheum Dis 2006; 65: 829-831
46. Braga CW, Martinez D, Wofchuk S, Portela LV, Souza DO. S100B and NSE serum levels in obstructive sleep apnea syndrome. Sleep Med 2006; 7: 431-435
47. Yang XY, Lin J, Lu XY, Zhao XY. Expression of S100B protein levels in serum and cerebrospinal fluid with different forms of neuropsychiatric systemic lupus erythematosus. Clin Rheumatol 2008; 27: 353-357
48. Leite MC, Brolese G, de Almeida LM, Pinero CC, Gottfried C, Goncalves CA. Ammonia-induced alteration in S100B secretion in astrocytes is not reverted by creatine addition. Brain Res Bull 2006; 70: 179-185
49. Andreazza AC, Cassini C, Rosa AR, et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res 2007; 41: 523-529
50. Sen J, Belli A. S100B in neuropathologic states: the CRP of the brain? J Neurosci Res 2007; 85: 1373-1380
51. Hsieh HL, Schafer BW, Sasaki N, Heizmann CW. Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res Commun 2003; 307: 375-381
52. Semov A, Moreno MJ, Onichtchenko A, et al. Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation. J Biol Chem 2005; 280: 20833-20841
53. Donato R. RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Current Mol Med 2007; 7: 711-724
54. Von Schoultz E, Hansson LO, Djureen E, et al. Prognostic value of serum analyses of S100B protein in malignant melanoma. Melanoma Res 1996; 6: 133-137
55. Faries MB, Gupta RK, Ye X, et al. A Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients. Cancer Invest 2007; 25: 285-293
56. Strobel K, Skalsky J, Kalff V, et al. Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B. Eur J Nucl Med Mol Imaging 2007; 34: 1366-1375
57. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol 2008; 35: 433-444.
58. Marchi N, Mazzone P, Fazio V, Mekhail T, Masaryk T, Janigro D. ProApolipoprotein A1: a serum marker of brain metastases in lung cancer patients. Cancer 2008; 112: 1313-1324
59. Nagy N, Hoyaux D, Gielen I, et al. The Ca2+-binding S100A2 protein is differentially expressed in epithelial tissue of glandular or squamous origin. Histol Histopathol 2002; 17: 123-130
60. Heighway J, Knapp T, Boyce L, et al. Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 2002; 21: 7749-7763
61. Wang H, Zhang Z, Li R, et al. Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancer. Int J Cancer 2005; 116: 285-290
62. Jassem E, Serkies K, Dziadziuszko R, et al. Prognostic value of S-100 immunostaining in tumour cells of non-small cell lung cancer. Biomarkers 2006; 11: 262-269
63. El-Rifai W, Moskaluk CA, Abdrabbo MK, et al. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 2002; 62: 6823-6826
64. Parfitt JR, McLean CA, Joseph MG, Streutker CJ, Al-Haddad S, Driman DK. Granular cell tumours of the gastrointestinal tract: expression of nestin and clinicopathological evaluation of 11 patients. Histopathology 2006; 48: 424-430
65. Li G, Gentil-Perret A, Lambert C, Genin C, Tostain J. S100A1 and KIT gene expressions in common subtypes of renal tumours. Eur J Surg Oncol 2005; 31: 299-303
66. Tsai ST, Jin YT, Tsai WC, et al. S100A2, a potential marker for early recurrence in early-stage oral cancer. Oral Oncol 2005; 41: 349-357
67. Kennedy RD, Gorski JJ, Quinn JE, et al. BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. Cancer Res 2005; 65: 10265-10272
68. Rafii S, Lyden D. S100 chemokines mediate bookmarking of premetastatic niches. Nat Cell Biol 2006; 8: 1321-1323
69. Fernandez-Fernandez MR, Veprintsev DB, Fersht AR. Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor. Proc Natl Acad Sci USA 2005; 102: 4735-4740
70. Markowitz J, Mackerell AD Jr, Carrier F, Charpentier TH, Weber DJ. Design of Inhibitors for S100B. Curr Top Med Chem 2005; 5: 1093-1108
71. Gieldon A, Mori M, Del Conte R. Theoretical study on binding of S100B protein. J Mol Model 2007; 13: 1123-1131
72. Ehlermann P, Remppis A, Guddat O, et al. Right ventricular upregulation of the Ca(2+) binding protein S100A1 in chronic pulmonary hypertension. Biochim Biophys Acta 2000; 1500: 249-255
73. Remppis A, Greten T, Schafer BW, et al. Altered expression of the Ca2+-binding protein S100A1 in human cardiomyopathy. Biochim Biophys Acta 1996; 1313: 253-257
74. Kiewitz R, Acklin C, Minder E, Huber PR, Schafer BW, Heizmann CW. S100A1, a new marker for acute myocardial ischemia. Biochem Biophys Res Commun 2000; 274: 865-871
75. Most P, Boerries M, Eicher C, et al. Extracellular S100A1 protein inhibits apoptosis in ventricular cardiomyocytes via activation of the extracellular signal-regulated protein kinase 1/2 (ERK1/2). J Biol Chem 2003; 278: 48404-48412
76. Grubb NR, Simpson C, Sherwood RA, et al. Prediction of cognitive dysfunction after resuscitation from out-of-hospital cardiac arrest using serum neuron-specific enolase and protein S-100. Heart 2007; 93: 1268-1273
77. Ekmektzoglou KA, Xanthos T, Papadimitriou L. Biochemical markers (NSE, S-100, IL-8) as predictors of neurological outcome in patients after cardiac arrest and return of spontaneous circulation. Resuscitation 2007; 75: 219-228
78. Pfeifer R, Borner A, Krack A, Sigusch HH, Surber R, Figulla HR. Outcome after cardiac arrest: predictive values and limitations of the neuroproteins neuron-specific enolase and protein S-100 and the Glasgow Coma Scale. Resuscitation 2005; 65: 49-55
79. Carrier M, Denault A, Lavoie J, Perrault LP. Randomized controlled trial of pericardial blood processing with a cell-saving device on neurologic markers in elderly patients undergoing coronary artery bypass graft surgery. Ann Thorac Surg 2006; 82: 51-55
80. Frosch M, Strey A, Vogl T, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000; 43: 628-637
81. Foell D, Wittkowski H, Hammerschmidt I, et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum 2004; 50: 1286-1295
82. Broome AM, Ryan D, Eckert RL. S100 protein subcellular localization during epidermal differentiation and psoriasis. J Histochem Cytochem 2003; 51: 675-685
83. Semprini S, Capon F, Tacconelli A, et al. Evidence for differential S100 gene over-expression in psoriatic patients from genetically heterogeneous pedigrees. Hum Genet 2002; 111: 310-313
84. Shishibori T, Oyama Y, Matsushita O, et al. Three distinct anti-allergic drugs, amlexanox, cromolyn and tranilast, bind to S100A12 and S100A13 of the S100 protein family. Biochem J 1999; 338: 583-589
85. Morbini P, Villa C, Campo I, Zorzetto M, Inghilleri S, Luisetti M. The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? Mod Pathol 2006; 19: 1437-1445
86. Esposito G, Cirillo C, Sarnelli G, et al. Enteric glial-derived S100B protein stimulates nitric oxide production in celiac disease. Gastroenterology 2007; 133: 918-925
87. Schulpis KH, Moukas M, Parthimos T, Tsakiris T, Parthimos N, Tsakiris S. The effect of alpha-Tocopherol supplementation on training-induced elevation of S100B protein in sera of basketball players. Clin Biochem 2007; 40: 900-906
88. Liappas I, Tzavellas EO, Kariyannis C, et al. Effect of alcohol detoxification on serum S-100B levels of alcohol-dependent individuals. In Vivo 2006; 20: 675-680
89. Florio P, Marinoni E, Di Iorio R, et al. Urinary S100B protein concentrations are increased in intrauterine growth-retarded newborns. Pediatrics 2006; 118: e747-e754
90. Salama I, Malone PS, Mihaimeed F, Jones JL. A review of the S100 proteins in cancer. Eur J Surg Oncol 2008; 34 : 357-364